TXG 10x Genomics, Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1770787 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.6%
TTM net income YoY12.1%
TTM EPS YoY17.5%
Revenue 3-yr CAGR1.5%
Net income 3-yr CAGR—
Margins
Gross margin71.9%
Operating margin-11.7%
Net margin-10.8%
FCF margin15.2%
EBITDA margin-5.3%
Returns
ROE-8.3%
ROA-6.4%
ROIC (approx.)-17.2%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets21.2%
Debt / equity0.00x
Current ratio5.12x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.49x
Accruals ratio-16.0%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $150.67M | $151.04M | $150.84M | $166.03M | $149.00M | $172.91M | $154.88M | $165.02M |
| Cost of revenue | $37.74M | $38.54M | $44.66M | $52.98M | $48.70M | $47.82M | $49.44M | $54.07M |
| Gross profit | $112.93M | $112.50M | $106.18M | $113.05M | $100.31M | $125.08M | $105.44M | $110.95M |
| R&D expense | $52.93M | $56.79M | $56.85M | $55.97M | $57.19M | $61.22M | $64.25M | $66.97M |
| SG&A expense | $76.06M | $78.66M | $66.38M | $76.62M | $75.36M | $74.43M | $89.73M | $93.83M |
| Operating income | -$16.06M | -$19.55M | -$17.05M | -$19.54M | -$32.24M | $30.13M | -$39.33M | -$49.84M |
| Interest expense | $0 | $0 | — | $0 | -$3,000 | $3,000 | $0 | $0 |
| Pretax income | -$18.48M | -$18.64M | -$12.85M | -$15.19M | -$28.20M | $37.00M | -$33.51M | -$48.38M |
| Income tax | $949,000 | -$714,000 | $623,000 | $1.06M | -$733,000 | $2.46M | $852,000 | $648,000 |
| Net income | -$19.43M | -$17.93M | -$13.47M | -$16.25M | -$27.47M | $34.54M | -$34.36M | -$49.03M |
| EBITDA | -$6.55M | -$9.89M | -$7.09M | -$9.48M | -$21.95M | $37.94M | -$31.31M | -$41.09M |
| EPS (basic) | -0.15 | -0.14 | -0.10 | — | -0.22 | 0.28 | -0.28 | — |
| EPS (diluted) | -0.15 | -0.14 | -0.10 | — | -0.22 | 0.28 | -0.28 | — |
| Weighted avg. shares (diluted) | 130.81M | 129.98M | 128.29M | — | 125.50M | 124.51M | 122.61M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $526.19M | $502.51M | $490.29M | $473.97M | $432.71M | $397.71M | $377.06M | $344.07M |
| Short-term investments | $49.49M | $49.52M | $49.56M | $49.44M | $49.58M | $49.55M | $49.84M | $49.34M |
| Receivables | $55.70M | $47.55M | $39.03M | $47.01M | $43.78M | $49.98M | $52.55M | $87.86M |
| Inventory | $64.63M | $52.62M | $53.49M | $56.34M | $61.96M | $68.97M | $74.71M | $83.11M |
| Current assets | $718.63M | $674.67M | $669.73M | $684.45M | $659.83M | $655.66M | $579.73M | $584.39M |
| PP&E, net | $210.24M | $215.32M | $220.59M | $226.71M | $232.53M | $239.71M | $246.09M | $252.65M |
| Goodwill | $6.92M | $6.92M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M |
| Intangibles | $58.66M | $61.16M | $59.91M | $62.33M | $64.76M | $14.71M | $15.19M | $15.67M |
| Total assets | $1.06B | $1.03B | $1.02B | $1.04B | $1.03B | $979.97M | $903.39M | $918.64M |
| Current liabilities | $140.37M | $118.51M | $113.60M | $153.45M | $147.32M | $112.22M | $107.90M | $117.63M |
| Total liabilities | $225.09M | $204.52M | $201.44M | $245.04M | $242.24M | $206.69M | $196.50M | $208.50M |
| Shareholders' equity | $838.04M | $825.55M | $814.32M | $796.33M | $785.12M | $773.28M | $706.89M | $710.13M |
| Shares outstanding | — | — | — | 127.69M | — | — | — | 122.29M |
| Cash flow statement | ||||||||
| Operating cash flow | $15.83M | $16.97M | $26.12M | $40.78M | $43.21M | $17.71M | $34.35M | -$6.75M |
| Capital expenditure | $971,000 | $1.59M | $1.60M | $1.78M | $687,000 | $1.58M | $1.89M | $2.72M |
| Free cash flow | $14.86M | $15.39M | $24.52M | $39.00M | $42.53M | $16.13M | $32.46M | -$9.46M |
| Investing cash flow | -$503,000 | -$7.74M | -$1.31M | -$1.80M | -$8.80M | -$939,000 | -$1.89M | -$51.59M |
| Financing cash flow | $8.53M | $3.02M | -$8.42M | $2.24M | $617,000 | $3.52M | $422,000 | $4.52M |
| Depreciation & amortization | $9.50M | $9.66M | $9.96M | $10.06M | $10.30M | $7.82M | $8.02M | $8.75M |
| Stock-based compensation | $23.10M | $25.62M | $22.64M | $25.22M | $25.26M | $27.25M | $31.08M | $32.54M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.